OncoMatch/Clinical Trials/NCT07320586

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Is NCT07320586 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Nab paclitaxel for gastric cancer.

Phase 2RecruitingShandong Tumor HospitalNCT07320586Data as of May 2026

Treatment: Camrelizumab · Nab paclitaxel — This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included in each population, and a total of 40 subjects were planned to be included.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Biomarker criteria

Required: HER2 (ERBB2) negative

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: systemic chemotherapy — first-line

Gastric cancer patients who have previously received first-line systemic chemotherapy (queue 1) or systemic chemotherapy combined with immunotherapy (queue 2) for progression

Cannot have received: paclitaxel (paclitaxel)

Patients who have received previous treatment with paclitaxel drugs

Lab requirements

Blood counts

absolute neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L

Kidney function

CrCl ≥ 60 ml/min/1.73 m2 (Cockcroft Gault formula)

Liver function

serum total bilirubin ≤ 1.5x ULN, AST and ALT ≤ 2.5x ULN (≤ 5x ULN if liver metastasis)

The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 10^9/L (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml/min/1.73 m2 (calculated according to the Cockcroft Gault formula);

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify